Phase 4Status unknown
Efficacy and Safety Study of 5 mg and 10 mg Rosuvastatin (Cor16)
An Open-label, Randomized, Multi-centre, Phase IVb, Parallel Study Group to Compare the Efficacy and Safety of 5 mg and 10 mg Rosuvastatin
- Sponsor
- D16 Pharma & Biotec Ltd. (Industry)
- Enrollment
- 2,000 planned
- Conditions
- Dyslipidemia
- Interventions
- Rosuvastatin 5 mg; Rosuvastatin 10 mg
- Ages
- adults, older adults
- Registry
- NCT01613729
Full record on ClinicalTrials.gov
From the registry
The primary objective of the study is to compare the efficacy of Rosuvastatin 5 mg once daily with Rosuvastatin 10 mg once daily by assessment of the number of patients with hypercholesterolemia reaching the LDL-C target goal of \<100 mg/dL after 12 weeks of therapy.
Primary outcomes
- Efficacy of Rosuvastatin 5 mg once daily with Rosuvastatin 10 mg once daily by assessment of the number of patients with hypercholesterolemia reaching the LDL-C target goal of <100 mg/dL after 12 weeks of therapy.
History
Study completion
Primary completion
Last registry update
Started
Registered